China Pharma (NYSE:CPHI) Shares Up 4.4% – Should You Buy?

Shares of China Pharma Holdings, Inc. (NYSE:CPHI) rose 4.4% during trading on Wednesday . The company traded as high as $0.6398 and last traded at $0.6140. Approximately 26,130 shares were traded during trading, a decline of 50% from the average daily volume of 51,986 shares. The stock had previously closed at $0.5882.

China Pharma Price Performance

The company has a current ratio of 0.79, a quick ratio of 0.26 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $3.21 million, a PE ratio of -1.12 and a beta of 1.20. The stock’s 50-day moving average is $0.75 and its two-hundred day moving average is $1.33.

Institutional Trading of China Pharma

An institutional investor recently raised its position in China Pharma stock. Citadel Advisors LLC lifted its stake in China Pharma Holdings, Inc. (NYSE:CPHI) by 31.9% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 30,426 shares of the company’s stock after purchasing an additional 7,356 shares during the period. Citadel Advisors LLC owned about 0.93% of China Pharma worth $59,000 at the end of the most recent quarter.

China Pharma Company Profile

China Pharma Holdings, Inc develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products to hospitals and private retailers in the People’s Republic of China. The company provides products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate injection to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Ozagrel Sodium to treat acute thrombotic cerebral infarction and dyskinesia; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension.